Regulatory T (Treg) cells play animportant role in the control of autoimmune diseases and maintenance oftolerance. The clinical use of Tregs requires large numbers of cells andmethods for invitro expansionof Tregs are being developed. Expansion of highly purified populations of humanTregs also frequently results in the loss of Foxp3 expression during theexpansion process.

There are two major subsets of Tregcells: “natural” Treg (nTreg)cells that develop in the thymus, and “induced” Treg (iTreg)cells that arise in the periphery from CD4+Foxp3- conventional T cells, which can begenerated invitro. Although they have slightly different phenotypes, their suppressive function is known to be very similar.

TREGableTM

TREGableTM is amethod to generate large number of nTreg (CD4+CD25hiCD127lo/-Foxp3+Helios+) without losing their suppressive activity according to TeraImmune’s proprietaryrecipe. It enables the expansion of Foxp3+ Tregs invitro,results in prolonged stabilization of the Foxp3+Helios+ subpopulation and yields an optimalpopulation for the clinical use.

TREGingTM

TREGingTM produces an immunosuppressive iTregs byculturing isolated conventional T cells (CD4+CD25hiCD127lo/-Foxp3+Helios+) or naïve T cells (CD4+CD25-/loCD127+CD45RA+)cells using TeraImmune’s proprietary recipe. It induces a conversion of these Tcells to iTregs (CD4+CD25+Foxp3+) within 2-3 weeks of expansion invitro. Theexpanded iTregsacquire nTreg-likeimmune suppressive function by TREGingTM technology.

B-cell antibody receptor (BAR)

Chimeric Antigen Receptors (CAR) arereceptor proteins that have been engineered to give T cells the new ability totarget a specific protein (e.g. CD19 on the surface of normal and neoplastic Bcells). The receptors are chimeric because they combine both antigen-bindingand T-cell activating functions into a single receptor.

The B-cell Antibody Receptor (BAR) is aTeraImmune’s cutting-edge technology that is designed to target the B CellReceptor (BCR) on the surface of B-cell subset. While the CD19 CAR recognizesall the B-cells expressing CD19 whether they are normal or neoplastic, BAR canspecifically recognize BCR of neoplastic B cell. Our BAR technology can abolishthe potential serious adverse events observed from the CD19-targeted CAR, suchas cytokine release syndrome and neurological toxicity.